Page contentsPage contentsKey factsDecisionKey facts Active Substance vixarelimab Therapeutic area Respiratory, thoracic and mediastinal disorders Decision number P/0095/2024 PIP number EMEA-003540-PIP01-23 Pharmaceutical form(s) Solution for injection Condition(s) / indication(s) Treatment of idiopathic pulmonary fibrosis Route(s) of administration Subcutaneous use Contact for public enquiries Roche Registration GmbHE-mail: global.paediatrics@roche.comTel. +41 6169 79411 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 12/04/2024DecisionP/0095/2024: EMA decision of 12 April 2024 on the granting of a product specific waiver for vixarelimab (EMEA-003540-PIP01-23)AdoptedReference Number: EMA/77767/2024 English (EN) (188.51 KB - PDF)First published: 06/06/2025ViewShare this page